Sarepta Therapeutics, Inc. – NASDAQ:SRPT

Add to watchlist

$19.8

-101.7

-83.7%

Market closed

Open in about 1 hour

-20.12%

month

-20.12%

quarter

+25.46%

year

Market Cap	11.27B
Enterprise value	11.93B

P/E	-16.72
EV/Sales	12.79
EV/EBITDA	-19.37
Price/Sales	12.11
Price/Book	29.36
PEG ratio	0.24
EPS	0.13

Revenue	1.40B
EBITDA	-52.88M
Income	16.89M
Revenue Q/Q	63.10%
Revenue Y/Y	43.82%

Profit margin	-75.4%
Oper. margin	-57.47%
Gross margin	85%
EBIT margin	-57.47%
EBITDA margin	-3.77%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sarepta Therapeutics Stock Forecast

M Q Y

Last Year

$185.78

Potential upside: 838.27%

Analysts Price target
Financials & Ratios estimates

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Profit margin
Jun 2023	261.23M	-23.94M	-9.16%
Sep 2023	331.81M	-40.93M	-12.34%
Dec 2023	396.78M	45.65M	11.51%
Mar 2024	413.46M	36.11M	8.74%

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Debt to assets
Jun 2023	3125890000	2.38B	76.28%
Sep 2023	3109707000	2.34B	75.42%
Dec 2023	3264576000	2.40B	73.68%
Mar 2024	3224385000	2.26B	70.19%

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Cash Flow
Jun 2023	-122.23M	96.63M	5.86M
Sep 2023	-114.70M	-210.57M	15.40M
Dec 2023	-54.65M	-64.35M	1.94M
Mar 2024	-242.07M	218.79M	22.14M

Sarepta Therapeutics alternative data

Sarepta Therapeutics
Employees

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Employee count
Aug 2023	1,162
Sep 2023	1,162
Oct 2023	1,162
Nov 2023	1,162
Dec 2023	1,162
Jan 2024	1,162
Feb 2024	1,162
Mar 2024	1,314
Apr 2024	1,314
May 2024	1,314
Jun 2024	1,314
Jul 2024	1,314

Sarepta Therapeutics
Hedge Funds Holdings Q1 2022

87.81% -12.19%

of SRPT is owned by hedge funds

312 -14

hedge funds hold SRPT stock

71.35M +347.23K

shares is hold by hedge funds

SRPT hedge funds holdings changes

Sarepta Therapeutics
Insider Trading

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Insider trades (number of shares)
Period	Buy	Sel
Mar 2024	0	24096
May 2024	0	3635
Jun 2024	0	50714
Aug 2024	37038	5985
Dec 2024	0	12136

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	12 Dec 2024	WIGZELL HANS LENNART RUDOLF director director	Common Stock	10,500	$13.71	$143,955
Sale	12 Dec 2024	WIGZELL HANS LENNART RUDOLF director director	Common Stock	10,500	$124.84	$1,310,820
Option	12 Dec 2024	WIGZELL HANS LENNART RUDOLF director director	Stock Options (right to buy)	10,500	$13.71	$143,955
Sale	5 Dec 2024	BOOR KATHRYN JEAN director director	Common Stock	1,636	$125.55	$205,400
Sale	30 Aug 2024	ESTEPAN IAN MICHAEL officer: Chief Fi..	Common Stock	5,985	$137.36	$822,100
Purchase	16 Aug 2024	CHAMBERS MICHAEL ANDREW director director	Common Stock	5,648	$134.66	$760,560
Purchase	16 Aug 2024	CHAMBERS MICHAEL ANDREW director director	Common Stock	18,284	$134.06	$2,451,153
Purchase	16 Aug 2024	CHAMBERS MICHAEL ANDREW director director	Common Stock	13,106	$133.07	$1,744,015
Option	3 Jul 2024	BEHRENS M KATHLEEN director director	Common Stock	15,000	$13.9	$208,500
Option	3 Jul 2024	BEHRENS M KATHLEEN director director	Stock Option (right to buy)	15,000	$13.9	$208,500

SRPT insider trading transactions

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Exon skipping oligomer conjugates for muscular dystrophy Filling date: 30 Apr 2021 Issue date: 26 Jul 2022	30 Apr 2021	26 Jul 2022
Grant	Grant Utility: Processes for preparing oligomers Filling date: 16 Nov 2020 Issue date: 12 Jul 2022	16 Nov 2020	12 Jul 2022
Grant	Grant Utility: Exon skipping oligomer conjugates for muscular dystrophy Filling date: 14 Dec 2017 Issue date: 12 Jul 2022	14 Dec 2017	12 Jul 2022
Grant	Grant Utility: Exon skipping oligomer conjugates for muscular dystrophy Filling date: 24 Jul 2020 Issue date: 24 May 2022	24 Jul 2020	24 May 2022
Application	Application ANTISENSE-INDUCED EXON EXCLUSION IN MYOSTATIN Filling date: 15 Apr 2021 Issue date: 24 Mar 2022	15 Apr 2021	24 Mar 2022
Application	Application COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY Filling date: 21 Oct 2021 Issue date: 3 Feb 2022	21 Oct 2021	3 Feb 2022
Application	Application ADENO-ASSOCIATED VIRUS ANTIBODIES AND FRAGMENTS THEREOF Filling date: 17 Sep 2021 Issue date: 3 Feb 2022	17 Sep 2021	3 Feb 2022
Grant	Grant Utility: Antisense-induced exon2 inclusion in acid alpha-glucosidase Filling date: 5 Sep 2014 Issue date: 1 Feb 2022	5 Sep 2014	1 Feb 2022
Application	Application EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY Filling date: 11 Jun 2021 Issue date: 20 Jan 2022	11 Jun 2021	20 Jan 2022
Grant	Grant Utility: Functionally-modified oligonucleotides and subunits thereof Filling date: 20 May 2019 Issue date: 28 Dec 2021	20 May 2019	28 Dec 2021

Sarepta Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 1 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 1 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

SRPT earnings call transcripts

Sarepta Therapeutics
Executives

Insider	Age	Compensation
Mr. Douglas S. Ingram (1963) Pres, Chief Executive Officer & Director	62	$1,290,000
Dr. Gilmore O'Neill M.D. (1965) Executive Officer	60	$891,940
Dr. Louise Rodino-Klapac Ph.D. (1978) Chief Scientific Officer and Head of R&D	47	$739,050
Mr. Ian Michael Estepan (1976) Executive Vice President & Chief Financial Officer	49	$684,120
Mr. William F. Ciambrone (1964) Executive Vice President of Technical Operations	61	$679,940
Mr. Joseph Bratica (1964) Controller & Vice President	61	$438,510

Sarepta Therapeutics
Latest News

Friday, 20 December 2024
16:45	Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku	reuters.com
Thursday, 19 December 2024
14:25	4 Biotech Stocks Most Wall Street Analysts Are Bullish About	zacks.com
09:45	SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder	zacks.com
Wednesday, 18 December 2024
08:30	Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4	businesswire.com
Tuesday, 17 December 2024
10:01	3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025	zacks.com
Friday, 13 December 2024
11:20	FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe	proactiveinvestors.com
10:56	Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?	zacks.com
Monday, 9 December 2024
06:48	Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?	zacks.com
Friday, 29 November 2024
16:10	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
15:01	Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?	zacks.com
Wednesday, 27 November 2024
12:35	SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies	zacks.com
11:00	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet	zacks.com
Tuesday, 26 November 2024
07:00	Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs	businesswire.com
Friday, 8 November 2024
15:02	Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step	seekingalpha.com
Thursday, 7 November 2024
10:20	SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program	zacks.com
02:10	Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 6 November 2024
19:36	Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates	zacks.com
Wednesday, 23 October 2024
08:30	Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results	businesswire.com
Thursday, 17 October 2024
09:53	2 High-Flying Growth Stocks With Massive Upside Potential	fool.com
Thursday, 3 October 2024
08:15	Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics	fool.com
Monday, 30 September 2024
16:39	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 26 September 2024
08:30	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress	businesswire.com
Wednesday, 18 September 2024
23:59	Sarepta Therapeutics Muscles Up In DMD Race	seekingalpha.com
11:40	3 Best High-Growth Mid-Cap Stocks to Buy in September 2024	247wallst.com
Friday, 13 September 2024
06:45	These 2 Biotech Stocks Are Set to Soar	fool.com
Friday, 6 September 2024
12:38	Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?	zacks.com
Friday, 30 August 2024
08:30	Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference	businesswire.com
Monday, 19 August 2024
13:43	Bull Signal Flashing for Sarepta Therapeutics Stock	schaeffersresearch.com
Wednesday, 14 August 2024
14:39	Biotech Stock Flashing Bull Signal	forbes.com
Monday, 12 August 2024
09:30	2 Biotech Stocks to Buy Hand Over Fist in August	fool.com

Ideas & Opinions

Seeking Alpha 28 Jul 2025

Sarepta Therapeutics: Beaten Down, But Not Out
Seeking Alpha 22 Jul 2025

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Seeking Alpha 18 Jul 2025

Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
Seeking Alpha 17 Jul 2025

Sarepta: Finally, A Little Relief For Bulls; I Expect More
Seeking Alpha 7 Jul 2025

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months
Seeking Alpha 16 Jun 2025

Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy
Seeking Alpha 16 Jun 2025

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
Seeking Alpha 16 Jun 2025

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom
Seeking Alpha 5 May 2025

Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict
Seeking Alpha 5 May 2025

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

Frequently Asked Questions (FAQ)

What's the price of Sarepta Therapeutics stock today?

One share of Sarepta Therapeutics stock can currently be purchased for approximately $19.8.
When is Sarepta Therapeutics's next earnings date?

Unfortunately, Sarepta Therapeutics's (SRPT) next earnings date is currently unknown.
Does Sarepta Therapeutics pay dividends?

No, Sarepta Therapeutics does not pay dividends.
How much money does Sarepta Therapeutics make?

Sarepta Therapeutics has a market capitalization of 11.27B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.26% to 1.24B US dollars.
What is Sarepta Therapeutics's stock symbol?

Sarepta Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SRPT".
What is Sarepta Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Sarepta Therapeutics?

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Sarepta Therapeutics's key executives?
Sarepta Therapeutics's management team includes the following people:
- Mr. Douglas S. Ingram Pres, Chief Executive Officer & Director(age: 62, pay: $1,290,000)
- Dr. Gilmore O'Neill M.D. Executive Officer(age: 60, pay: $891,940)
- Dr. Louise Rodino-Klapac Ph.D. Chief Scientific Officer and Head of R&D(age: 47, pay: $739,050)
- Mr. Ian Michael Estepan Executive Vice President & Chief Financial Officer(age: 49, pay: $684,120)
- Mr. William F. Ciambrone Executive Vice President of Technical Operations(age: 61, pay: $679,940)
- Mr. Joseph Bratica Controller & Vice President(age: 61, pay: $438,510)
How many employees does Sarepta Therapeutics have?

As Jul 2024, Sarepta Therapeutics employs 1,314 workers.
When Sarepta Therapeutics went public?

Sarepta Therapeutics, Inc. is publicly traded company for more then 28 years since IPO on 4 Jun 1997.
What is Sarepta Therapeutics's official website?

The official website for Sarepta Therapeutics is sarepta.com.
Where are Sarepta Therapeutics's headquarters?

Sarepta Therapeutics is headquartered at 215 First Street, Cambridge, MA.
How can i contact Sarepta Therapeutics?

Sarepta Therapeutics's mailing address is 215 First Street, Cambridge, MA and company can be reached via phone at +61 72744000.
What is Sarepta Therapeutics stock forecast & price target?

Based on 8 Wall Street analysts` predicted price targets for Sarepta Therapeutics in the last 12 months, the avarage price target is $185.78. The average price target represents a 838.27% change from the last price of $19.8.

Sarepta Therapeutics, Inc.

sarepta.com

Exchange:

NASDAQ

Full time employees:

1,314

Industry:

Biotechnology

Sector:

Healthcare

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

+61 72744000

215 First Street
Cambridge, MA 02142

CIK: 0000873303
ISIN: US8036071004
CUSIP: 803607100